Moreover, FXR agonists, like GSK2324, are employed in the treatment of NAFLD due to their role in decreasing fatty acid absorption and selectively reducing fatty acid synthesis [72]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.